Cargando…

Improving Interactions Between Health Technology Assessment Bodies and Regulatory Agencies: A Systematic Review and Cross-Sectional Survey on Processes, Progress, Outcomes, and Challenges

The need to optimize drug development and facilitate faster access for patients has ignited discussions around the importance of improving interactions between health technology assessment (HTA) bodies and regulatory agencies. In this study, we conducted a systematic review to examine processes, pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ofori-Asenso, Richard, Hallgreen, Christine E., De Bruin, Marie Louise
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596325/ https://www.ncbi.nlm.nih.gov/pubmed/33178721 http://dx.doi.org/10.3389/fmed.2020.582634

Ejemplares similares

Impact of regulatory interventions to restrict the combined use of renin–angiotensin system blockers: A Danish nationwide drug utilisation study
por: Sindahl, Per, et al.
Publicado: (2021)

Mandatory requirements for pediatric drug development in the EU and the US for novel drugs—A comparative study
por: Christiansen, Helle, et al.
Publicado: (2022)

Establishment of the African Medicines Agency: progress, challenges and regulatory readiness
por: Ncube, Bakani Mark, et al.
Publicado: (2021)

“When the Bug Cannot Be Killed”—The Rising Challenge of Antimicrobial Resistance
por: Ofori-Asenso, Richard
Publicado: (2017)

Regulatory Science to 2025: An Analysis of Stakeholder Responses to the European Medicines Agency's Strategy
por: Hines, Philip A., et al.
Publicado: (2020)

The Use of Remote Monitoring Technologies: A Review of Recent Regulatory Scientific Advices, Qualification Opinions, and Qualification Advices Issued by the European Medicines Agency
por: Dekker, Marieke J. H. J., et al.
Publicado: (2021)

Are monitoring instructions provided in direct healthcare professional communications (DHPCs) of sufficient quality? A retrospective analysis of DHPCs sent out between 2007 and 2018
por: Højer, Maja-Marie Grønfeldt, et al.
Publicado: (2020)

A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach
por: Mulder, Jorn, et al.
Publicado: (2022)

Health horizons: Future trends and technologies from the European Medicines Agency’s horizon scanning collaborations
por: Vignali, Valentina, et al.
Publicado: (2022)

Involvement of the European Medicines Agency in multi-stakeholder regulatory science research projects: experiences of staff members and project coordinators
por: Saesen, Robbe, et al.
Publicado: (2023)

Guidance for pediatric use in prescription information for novel medicinal products in the EU and the US
por: Christiansen, Helle, et al.
Publicado: (2022)

Assessing Technologies for COVID-19: What are the Challenges for Health Technology Assessment Agencies? Findings From a Survey and Roundtable Workshop
por: Elvidge, Jamie, et al.
Publicado: (2021)

Epidemiological studies for regulatory agencies.
por: Hunt, V R
Publicado: (1981)

What is the process of obtaining informed consent in a clinical trial? Is it ever justifiable to include someone in a clinical trial without prior informed consent from the individual?
por: Agyeman, Akosua Adom, et al.
Publicado: (2016)

Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies
por: Lehoux, Pascale, et al.
Publicado: (2017)

Real-world evidence (RWE): A challenge for regulatory agencies discussion of the RWE conference with the network of the european medicine agencies, patients, and experts
por: Maison, Patrick, et al.
Publicado: (2022)

Decisions by regulatory agencies: are they evidence-based?
por: Furberg, Curt D
Publicado: (2007)

The regulatory challenges of innovative customized combination products
por: Reis, Mariana E., et al.
Publicado: (2022)

Agency as conversion process
por: Bazzani, Giacomo
Publicado: (2022)

A closer look at the World Health Organization's prescribing indicators
por: Ofori-Asenso, Richard
Publicado: (2016)

The Challenge to the Voluntary Health Agency
por: Platt, Philip S.
Publicado: (1947)

HTA Agencies Need Evidence-Informed Deliberative Processes Comment on "Use of Evidence-Informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe"
por: Schlander, Michael
Publicado: (2020)

Alignment of European Regulatory and Health Technology Assessments: A Review of Licensed Products for Alzheimer's Disease
por: Dekker, Marieke J. H. J., et al.
Publicado: (2019)

Cancer is associated with severe disease in COVID-19 patients: a systematic review and meta-analysis
por: Ofori-Asenso, Richard, et al.
Publicado: (2020)

Sense of body ownership and body agency in schizophrenia
por: Rossetti, Ileana, et al.
Publicado: (2022)

International regulatory agencies: Indian clinical trials
por: Bhatt, Arun
Publicado: (2011)

Regulatory Agencies and PET/CT Imaging in the Clinic
por: Herscovitch, Peter
Publicado: (2022)

The Diagnostic Accuracy of Syndromic Management for Genital Ulcer Disease: A Systematic Review and Meta-Analysis
por: Loh, Andre J. W., et al.
Publicado: (2022)

Time to improve transparency at Health Canada’s Pest Management Regulatory Agency
por: Gagnon, Marc-André, et al.
Publicado: (2023)

Deliberative Processes by Health Technology Assessment Agencies: A Reflection on Legitimacy, Values and Patient and Public Involvement Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe"
por: Goetghebeur, Mireille, et al.
Publicado: (2020)

A Regulatory Risk-Based Approach to ATMP/CGT Development: Integrating Scientific Challenges With Current Regulatory Expectations
por: Salazar-Fontana, Laura I.
Publicado: (2022)

HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES: A SURVEY OF NON-EUROPEAN UNION AGENCIES
por: Ciani, Oriana, et al.
Publicado: (2015)

The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway Approach
por: Nicotera, Giuseppe, et al.
Publicado: (2019)

Use of Evidence-Informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe
por: Oortwijn, Wija, et al.
Publicado: (2019)

Subretinal Therapy: Technological Solutions to Surgical and Immunological Challenges
por: Ladha, Reza, et al.
Publicado: (2022)

Triggering Postural Movements With Virtual Reality Technology in Healthy Young and Older Adults: A Cross-Sectional Validation Study for Early Dementia Screening
por: Imaoka, Yu, et al.
Publicado: (2020)

Biomarker and Companion Diagnostics—A Review of Medicinal Products Approved by the European Medicines Agency
por: Orellana García, Laura Patricia, et al.
Publicado: (2021)

Regulatory Challenges for Cartilage Repair Technologies
por: McGowan, Kevin B., et al.
Publicado: (2013)

Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies
por: Spelsberg, Angela, et al.
Publicado: (2017)

Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis
por: Morrow, Richard L, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5avl15gd9n8rf37f6bdb2vl6k6